NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System
← catalyst calendarNCT07018596 · readout ≤ 73 d
Sponsored by Pulse Biosciences, Inc. (industry) · PLSE — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
215estimated
Sites
1
Country
Czechia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-06 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atrial Fibrillation Paroxysmal
- Cardiac Ablation
- Cardiac Arrhythmia
Intervention
- Device: CellFX nsPFA Cardiac Catheter System
Primary outcomes
what the primary-completion date above is the date OFProportion of participants with freedom from primary safety endpoint
measured Within 7 days, 30 days, and 6 months post-ablation procedure
Proportion of participants achieving freedom from treatment failure.
measured 6 months post-ablation
Permalink · PLSE's whole pipeline · Catalyst calendar · Every registered study · What changed